Galera Therapeutics Advances Mid Stage Clinical Trial of GC4419
Galera Therapeutics Inc. (GRTX) reported that it has completed the process of patient enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. The drug candidate is being assessed for safety and anti-cancer efficacy when used in combination with stereotactic body radiation therapy in patients suffering from locally advanced pancreatic cancer.
Phase 1b/2a trial is a randomized study which will focus on determining progression-free survival and overall response rate of the drug candidate. It will also evaluate the safety and tolerability of